Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Nabiqasim Industries (Pvt) Ltd
800 participants
Oct 30, 2025
INTERVENTIONAL
Conditions
Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06862739